Previous close | 0.7500 |
Open | 1.5000 |
Bid | 0.7000 |
Ask | 1.5000 |
Strike | 15.00 |
Expiry date | 2024-05-17 |
Day's range | 0.7500 - 1.5000 |
Contract range | N/A |
Volume | |
Open interest | 14 |
BEDFORD, Mass., May 17, 2024--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on May 15, 2024, the company granted stock options of common stock to Thomas Leggett, the Company’s newly-appointed Chief Financial Officer, and four other new employees as a material inducement to their employment in accordance with Nasdaq Listing
Despite Narrow Miss on EPS, Stoke Therapeutics Advances in Clinical Developments
Stoke Therapeutics ( NASDAQ:STOK ) First Quarter 2024 Results Key Financial Results Net loss: US$26.4m (loss widened by...